MoonLake Immunotherapeutics — Investor Relations & Filings
Filings indexed
283
across all filing types
Latest filing
2026-05-11
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
MLTX
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-05-11 | English | |
| 8-K - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-05-11 | English | |
| 10-K - MOONLAKE IMMUNOTHERAPEUTICS (0001821586) (Filer) | 2026-02-25 | English | |
| 8-K - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-02-23 | English | |
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| Director's Dealing 2026 | 2026-01-09 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 44961427 | 10-Q - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-05-11 | English | ||
| 44942716 | 8-K - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-05-11 | English | ||
| 32899018 | 10-K - MOONLAKE IMMUNOTHERAPEUTICS (0001821586) (Filer) | 2026-02-25 | English | ||
| 32826316 | 8-K - MoonLake Immunotherapeutics (0001821586) (Filer) | 2026-02-23 | English | ||
| 31898078 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 13296456 | Director's Dealing 2026 | 2026-01-09 | English | ||
| 13296458 | Director's Dealing 2026 | 2026-01-09 | English | ||
| 13296457 | Director's Dealing 2026 | 2026-01-09 | English | ||
| 13296459 | CURRENT REPORT | 2026-01-08 | English | ||
|
2025
6 filings
| |||||
| 13296460 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13296461 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13296462 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13296463 | Director's Dealing 2025 | 2025-12-10 | English | ||
| 13296464 | Director's Dealing 2025 | 2025-12-10 | English | ||
| 13296465 | Regulatory Filings 2025 | 2025-12-08 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
MoonLake Immunotherapeutics via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33042/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33042 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33042 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33042 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33042}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MoonLake Immunotherapeutics (id: 33042)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.